Karyopharm Therapeutics Newsroom

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3

Moomoo NewsNov 15 07:33 ET

Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes

TipRanksNov 8 02:31 ET

Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $5

Moomoo NewsNov 6 08:38 ET

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3

Moomoo NewsNov 6 07:34 ET

Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsNov 6 03:33 ET

H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsNov 5 12:31 ET

Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating

TipRanksNov 5 11:38 ET

Karyopharm Therapeutics Analyst Ratings

BenzingaNov 1 05:52 ET

Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsNov 1 03:32 ET

H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsOct 31 12:31 ET

Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $4

Moomoo NewsOct 23 08:31 ET

Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)

TipRanksOct 23 07:42 ET

Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties

TipRanksAug 9 05:49 ET

Karyopharm Therapeutics (KPTI) Gets a Buy From RBC Capital

TipRanksAug 7 07:29 ET

Buy Rating Affirmed for Karyopharm Therapeutics Amid Strong Q2 Performance and Positive Xpovio Sales Outlook

TipRanksAug 7 06:49 ET

Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsAug 7 04:35 ET

Karyopharm Therapeutics Analyst Ratings

BenzingaJun 28 13:29 ET

Karyopharm Therapeutics Analyst Ratings

BenzingaJun 3 06:27 ET

Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)

TipRanksJun 3 05:43 ET

Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook

TipRanksMay 10 01:45 ET